(2S)-2-benzyloxycarbonylamino-3-(4-(3-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)propyloxy)phenyl)-propionic acid | 228572-40-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-benzyloxycarbonylamino-3-(4-(3-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)propyloxy)phenyl)-propionic acid
• 英文别名: (2S)-2-Benzyloxycarbonylamino-3-(4-(3-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)propyloxy)phenyl)propionic Acid；(2S)-3-[4-[4-oxo-4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)butoxy]phenyl]-2-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 228572-40-5
• 化学式: C₂₅H₃₀N₄O₆
• 分子量: 482.536
• InChiKey: GWIKTGZMCPFFRW-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2S)-2-benzyloxycarbonylamino-3-(4-(3-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)propyloxy)phenyl)-propionic acid 在 氯化亚砜 作用下， 以 乙醇 、 水 为溶剂， 生成 Ethyl (2S)-2-Benzyloxycarbonylamino-3-(4-(3-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)propyloxy)phenyl)propionate Hydrochloride
  参考文献：
  名称：

  Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists

  摘要：

  本发明涉及式(I)的酰基胍衍生物，其中R1、R2、R4、R5、R6、A、m和n具有专利要求中指示的含义，它们的生理耐受盐和前药。式(I)化合物是有价值的药用活性成分。它们是维脱内钙蛋白受体拮抗剂，能抑制破骨细胞对骨骼的吸收，例如，适用于治疗或预防至少部分由于不良骨吸收引起的疾病，例如骨质疏松症。该发明还涉及制备式(I)化合物的方法，它们的使用，特别是作为药用活性成分，并包含它们的药物制剂。

  公开号：

  US06492356B1

文献信息

• Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
  申请人：Hoechst Marion Roussel Deutschland GmbH

  公开号：EP0933367A1

  公开（公告）日：1999-08-04

  The present invention relates to acylguanidine derivatives of the formula I in which R1, R2, R4, R5, R6, A, m and n have the meanings indicated in the patent claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmaceutical active ingredients. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts and are suitable, for example, for the therapy or prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as pharmaceutical active ingredients, and pharmaceutical preparations comprising them.

  本发明涉及式 I 的酰基胍衍生物，其中 R1、R2、R4、R5、R6、A、m 和 n 具有专利权利要求中的含义。 中 R1、R2、R4、R5、R6、A、m 和 n 的含义，以及它们的生理耐受盐和原药。式 I 的化合物是有价值的药物活性成分。它们是维龙素受体拮抗剂和破骨细胞骨吸收抑制剂，适用于治疗或预防至少部分由不希望的骨吸收程度引起的疾病，例如骨质疏松症。本发明还涉及式 I 化合物的制备工艺、其用途（尤其是作为药物活性成分）以及包含它们的药物制剂。
• NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1042301B1

  公开（公告）日：2002-11-20
• Galenic Applications of Self-Emulsifying Mixtures of Lipidic Excipients
  申请人：Pachot Jean

  公开号：US20080193519A1

  公开（公告）日：2008-08-14

  A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.
• GALENIC APPLICATIONS OF SELF-EMULSIFYING MIXTURES OF LIPIDIC EXCIPIENTS
  申请人：Pachot Jean

  公开号：US20110104268A1

  公开（公告）日：2011-05-05

  A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.
• US6492356B1
  申请人：——

  公开号：US6492356B1

  公开（公告）日：2002-12-10